U.K. says new cancer therapy is too expensive

The Novartis headquarters building in Switzerland.
Novartis makes Kymriah, a new cancer treatment. Photo: Fabrice Coffrini/AFP via Getty Images

NICE, the governmental group in the United Kingdom that evaluates the value of drugs and treatments, has recommended against the use of a new $371,000 cancer therapy made by Novartis. It said the drug is "too expensive" for the population it would treat and that Novartis' "confidential discount" was not steep enough.

Why it matters: NICE's recommendation comes about a month after it said a similar treatment, known as CAR-T and made by Gilead Sciences, also is too pricey. An independent U.S. body said this year the two therapies were mostly cost-effective, but their high price tags still worry clinicians and policymakers.

FDA to outline antibiotic strategy

Dr. Scott Gottlieb
FDA Commissioner Scott Gottlieb. Photo: Drew Angerer/Getty Images

FDA Commissioner Scott Gottlieb will announce the agency's new approach to antimicrobial resistance today, including ideas for encouraging drugmakers to come up with new antibiotics.

The details: The plan also includes steps to promote careful antibiotic stewardship in human and animal medicine, and new tools to better collect data on antimicrobial use and when pathogens become resistant.